Diagnosis and risk stratification of PI-RADS v2.1 category 3–5 lesions using amide proton transfer imaging - Top-Institutions - MDSpire

Diagnosis and risk stratification of PI-RADS v2.1 category 3–5 lesions using amide proton transfer imaging

  • By

  • Hongkun Fang

  • Weishu Hou

  • Qun Wang

  • Xiaoyu Zhang

  • Xiao Wang

  • Shuhai Zhang

  • Shoubin Li

  • Xiaohu Li

  • Yongqiang Yu

  • May 6, 2025

  • 0 min

Share

Top Institutions in Urology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Radiology
    • Urologic Oncology
    • Cancer Imaging

  • #2

    National Cancer Institute (NCI), NIH
    National Cancer Institute (NCI), NIH

    Bethesda, MD

    Key Differentiators

    • Radiology
    • Oncology
    • Cancer Imaging Research

  • #3

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Radiology
    • Urology
    • Cancer Imaging

  • #4

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Urology
    • Radiology
    • Oncology

  • #5

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Radiology
    • Urology
    • Cancer Imaging

Original Source(s)

Diagnosis and risk stratification of PI-RADS v2.1 category 3–5 lesions using amide proton transfer imaging

  • by Hongkun Fang, Weishu Hou, Qun Wang, Xiaoyu Zhang, Xiao Wang, Shuhai Zhang, Shoubin Li, Xiaohu Li, Yongqiang Yu

  • May 6, 2025

Related Content

Artificial intelligence to improve cytology performance in urothelial carcinoma diagnosis: results from validation phase of the French, multicenter, prospective VISIOCYT1 trial

Novel contrast-enhanced ultrasound imaging in prostate cancer

Impact of the PI-QUAL MRI quality score on histopathological up-staging from MRI fusion biopsy to final prostatectomy specimen